Clinical Trial

Safety and Efficacy of Autologous iNSC-DAP in the Treatment of Parkinson's Disease

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase I, interventional, single arm, open-label, clinical study to evaluate the safety and efficacy of the striatal transplantation of autologous induced neural stem cell-derived DA precursor cells in Parkinson's Disease patients.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-06-05; most recent amendment 2026-06-29.
Trial Details
NCT Number NCT05901818
Lead Sponsor Xuanwu Hospital, Beijing
Conditions Parkinson's Disease
Enrollment 6 participants
Start Date 2021-04-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-01